A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808)

被引：0
|
作者：
Hiroyuki Uetake
Masamichi Yasuno
Megumi Ishiguro
Shingo Kameoka
Yasuhiro Shimada
Keiichi Takahashi
Toshiaki Watanabe
Kei Muro
Hideo Baba
Junji Yamamoto
Nobuyuki Mizunuma
Hiroshi Tamagawa
Izumi Mochizuki
Yusuke Kinugasa
Takashi Kikuchi
Kenichi Sugihara
机构：
[1] Tokyo Medical and Dental University,Department of Translational Oncology, Graduate School
[2] Tokyo Metropolitan Hiroo Hospital,Department of Surgery
[3] Tokyo Women’s Medical University,Department of Surgery II
[4] National Cancer Center Hospital,Division of Gastrointestinal Medical Oncology
[5] Tokyo Metropolitan Cancer and Infectious Disease Center,Colorectal Surgical Division, Department of Surgery
[6] Komagome Hospital,Department of Surgical Oncology, Graduate School of Medicine
[7] The University of Tokyo,Clinical Oncology
[8] Aichi Cancer Center Hospital,Department of Gastroenterological Surgery, Graduate School of Medical Science
[9] Kumamoto University,Department of Surgery
[10] National Defense Medical College,Gastroenterological Center
[11] Cancer Institute Hospital of Japanese Foundation for Cancer Research,Department of Surgery
[12] Osaka General Medical Center,Department of Surgery
[13] Iwate Prefectural Central Hospital,Gastrointestinal Surgery Division
[14] Shizuoka Cancer Center,Department of Statistical Analysis
[15] Translational Research Informatics Center,Department of Surgery Oncology
[16] Tokyo Medical and Dental University,undefined
来源：
Annals of Surgical Oncology | 2015年 / 22卷
关键词：
Bevacizumab; Liver Metastasis; Sixth Cycle; Resectable Liver Metastasis; High Adverse Event;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：908 / 915
页数：7
相关论文
共 50 条
  • [31] MFOLFOX6 plus CEDIRANIB VS MFOLFOX6 plus BEVACIZUMAB IN PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED, DOUBLE-BLIND, PHASE II/III STUDY (HORIZON III)
    Schmoll, H.
    Cunningham, D.
    Sobrero, A.
    Karapetis, C.
    Rougier, P.
    Koski, S. L.
    Barker, P.
    Mookerjee, B.
    Robertson, J.
    van Cutsem, E.
    ANNALS OF ONCOLOGY, 2010, 21 : 189 - 189
  • [32] Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA
    Gruenberger, Thomas
    Bridgewater, John A.
    Chau, Ian
    Garcia Alfonso, Pilar
    Rivoire, Michel
    Lasserre, Susan
    Waterkamp, Daniel
    Adam, Rene
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] A phase II multicenter trial of mFOLFOX6 as adjuvant treatment after resection of liver metastases from colorectal cancer (Miyagi-HBPCOG Trial-001): The final data of progression-free survival
    Katayose, Yu
    Yamamoto, Kuniharu
    Takemura, Shinichi
    Takahashi, Michinaga
    Nakamura, Ryuji
    Shimamura, Hiromune
    Asanuma, Taku
    Uchiyama, Tetsuyuki
    Endo, Kojin
    Oikawa, Masaya
    Shiiba, Kenichi
    Nakagawa, Kei
    Egawa, Shinichi
    Unno, Michiaki
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] PHASE II TRIAL OF mFOLFOX6/CapeOX PLUS BEVACIZUMAB WITH OXALIPLATIN IN A STOP AND GO FASHION IN ADVANCED mCRC
    Gamoh, M.
    Shimodaira, H.
    Murakawa, Y.
    Kato, S.
    Amagai, K.
    Isoge, H.
    Niitani, T.
    Itoh, J.
    Yoshioka, T.
    Ishioka, C.
    ANNALS OF ONCOLOGY, 2013, 24
  • [35] Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer
    Bekaii-Saab, Tanios S.
    Balser, Sigrid
    Lohmann, Ragna
    Daoud, Hasan
    Liedert, Bernd
    Schliephake, Dorothee
    COLORECTAL CANCER, 2022, 11 (01)
  • [36] A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08
    Wolmark, N.
    Yothers, G.
    O'Connell, M. J.
    Sharif, S.
    Atkins, J. N.
    Seay, T. E.
    Feherenbacher, L.
    O'Reilly, S.
    Allegra, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis
    Kim, Kyung Hwan
    Shin, Sang Joon
    Cho, Min Soo
    Ahn, Joong Bae
    Jung, Minkyu
    Kim, Tae Ii
    Park, Young Suk
    Kim, Hoguen
    Kim, Nam Kyu
    Koom, Woong Sub
    RADIOTHERAPY AND ONCOLOGY, 2016, 118 (02) : 369 - 374
  • [38] A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08
    Wolmark, N.
    Yothers, G.
    O'Connell, M. J.
    Sharif, S.
    Atkins, J. N.
    Seay, T. E.
    Feherenbacher, L.
    O'Reilly, S.
    Allegra, C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [39] PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
    Schwartzberg, Lee S.
    Rivera, Fernando
    Karthaus, Meinolf
    Fasola, Gianpiero
    Canon, Jean-Luc
    Hecht, J. Randolph
    Yu, Hua
    Oliner, Kelly S.
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (21) : 2240 - +
  • [40] TRICC-c: BIBF 1120 versus placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal cancer (mCRC)-A multicenter, randomized phase II trial in progress
    Berger, Andreas
    Ettrich, Thomas
    Marten, Angela
    Seufferlein, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345